about
The role of concomitant extracorporeal photopheresis for the treatment of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantationThe role of concomitant extracorporeal photopheresis for the treatment of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantationAcute graft-versus-host disease: a bench-to-bedside update.Graft versus host disease: New insights into A2A receptor agonist therapyBone marrow mesenchymal stromal cells to treat complications following allogeneic stem cell transplantation.Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre studyThe Free Radical Scavenger NecroX-7 Attenuates Acute Graft-versus-Host Disease via Reciprocal Regulation of Th1/Regulatory T Cells and Inhibition of HMGB1 Release.Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter surveyPreclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?MicroRNAs: The Missing Link in the Biology of Graft-Versus-Host Disease?ST2 as a marker for risk of therapy-resistant graft-versus-host disease and deathBone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses.Pathophysiology of GvHD and Other HSCT-Related Major Complications.The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter I: current practice and remaining unmet medical needs.Angiogenic factors and inflammation in steroid-refractory acute graft-vs-host disease.Pilot study of lithium to restore intestinal barrier function in severe graft-versus-host diseaseA risk-adapted approach to acute GVHD treatment: are we there yet?Altered homeostatic regulation of innate and adaptive immunity in lower gastrointestinal tract GVHD pathogenesis.Lithothamnion muelleri controls inflammatory responses, target organ injury and lethality associated with graft-versus-host disease in mice.Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis.Development of a biomarker scoring system for use in graft-versus-host disease.The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.Paternal bone marrow infusion as salvage therapy for severe GVHD following maternal haploidentical transplantation resulting in biparental chimerism.Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease.Placenta-Derived Decidua Stromal Cells for Treatment of Severe Acute Graft-Versus-Host Disease.Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective study.
P2860
Q24186279-BE83C250-420F-40C7-A550-C10CD4F2AC0BQ24198004-C8157D40-9734-490D-9142-5157DEF076FEQ27687130-AF061B94-5C65-462A-A778-DC896A738B2BQ28080809-7DA3C4A9-2F0D-4F60-8CE2-2561BB79DA05Q33648765-4AA9B4C0-7113-40AB-9816-77C347E3AFB0Q34093615-822F0CD1-151D-40D5-9E8A-BCEC029F7373Q35120338-7BE45384-96F0-49BE-9E09-64517BE1F023Q35609254-AC397C63-EE32-4AF6-92BD-4973970F8D04Q36862931-7F11E398-C4F4-4127-AB73-F634B9F7CEDAQ37035815-65CACE26-F5E1-4E9D-8A66-A2D22FF26058Q37352764-B9FBA8D4-6C1A-43B2-919E-047C53309929Q37618997-7F944B00-343F-4F71-854D-A6A0644FAE5AQ37710227-65CB0B15-37CC-4FEA-918C-DCF960D66A4EQ37710572-CD070699-1378-40A8-AB08-0E2C8F90B626Q38453666-8A7AB8C9-2BFE-4E15-B52B-698BBE2DC73CQ38539063-1739A168-FD42-43E0-9326-681F0D8E5D13Q38619812-DE29ABD4-5840-41B3-8321-85D392E7B866Q38628944-82A06491-8DCC-4A65-9469-57D60F1CDB7EQ38743931-4E5EF244-287B-4938-9E8C-E035B21AAE07Q39122603-680E1D9B-39FE-45F9-9036-3E3DDC92D5CBQ40119705-D8D25BB8-2303-4238-B0F9-ECF4AE6177FAQ40983696-0059E6A5-A509-4427-8255-E6CE8654C3F4Q41789683-7FAF5FEF-91DF-4CBD-A15A-F146949016CAQ42267482-B4491F7D-F5FE-44DC-906C-F9A2A3B8E6F0Q44847537-DEA5AFDE-1248-4554-AAD2-C4EB83F08D09Q52658261-1E1B3314-4879-4A7D-8D07-F77D8CE41A63Q55319551-F5256F88-633A-483F-BA41-EF235CA7CD25
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Steroid-Refractory Acute GVHD: Predictors and Outcomes.
@ast
Steroid-Refractory Acute GVHD: Predictors and Outcomes.
@en
type
label
Steroid-Refractory Acute GVHD: Predictors and Outcomes.
@ast
Steroid-Refractory Acute GVHD: Predictors and Outcomes.
@en
prefLabel
Steroid-Refractory Acute GVHD: Predictors and Outcomes.
@ast
Steroid-Refractory Acute GVHD: Predictors and Outcomes.
@en
P2093
P2860
P356
P1476
Steroid-Refractory Acute GVHD: Predictors and Outcomes
@en
P2093
Amin Alousi
Borje S Andersson
Daniel R Couriel
Elizabeth J Shpall
Gabriela Rondon
Issa F Khouri
Jason R Westin
Marcos De Lima
Muzaffar H Qazilbash
Paolo Anderlini
P2860
P304
P356
10.1155/2011/601953
P577
2011-11-03T00:00:00Z